Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
Glenn J. Hanna(Dana-Farber Cancer Institute), Jochen H. Lorch(Northwestern University), Krystof Misiwkeiwicz(Mount Sinai Hospital), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Pasi A. Jänne(Harvard University), Sewanti Limaye(Dana-Farber Cancer Institute), Matthew A. Nehs(Brigham and Women's Hospital), Ellen Marqusee(Brigham and Women's Hospital), Guilherme Rabinowits(Baptist Hospital of Miami), Justine A. Barletta(Brigham and Women's Hospital), Stephanie L. Lee(Boston Medical Center), Robert I. Haddad(Georgetown University), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Erik K. Alexander(Mass General Brigham), Antonio Calles(Dana-Farber Cancer Institute), Tom Thomas(Dana-Farber Cancer Institute), Stefan Kraft(Massachusetts General Hospital), Francis D. Moore(Brigham and Women's Hospital), Nicole G. Chau(University of British Columbia), Anne O’Neill(International Breast Cancer Study Group), Lori J. Wirth(Massachusetts General Hospital)
Cited by 125
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k